The effects of fluoxetine and its complexes with glycerrhizic acid on behavior in rats and brain monoamine levels

Neuroscience and Behavioral Physiology

Volumn 36, Issue 4, 2006, Pages 329-333

  Shishkina, G T ^a   Dygalo, N N ^a   Yudina, A M ^a   Kalinina, T S ^a   Tolstikova, T G ^b   Sorokina, I V ^b   Kovalenko, I L ^b   Anikina, L V ^b  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b N N VOROZHTSOV NOVOSIBIRSK INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

Author keywords

5 hydroxyindoleacetic acid; Anxiety; Dihydroxyphenylacetic acid; Dopamine; Elevated cross maze; Fluoxetine; Glycyrrhizic acid; Noradrenaline; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; FLUOXETINE; GLYCYRRHIZIC ACID; MONOAMINE; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR CONTROL; BODY MOVEMENT; BRAIN CORTEX; CATABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG POTENTIATION; HYPOTHALAMUS; MALE; MAZE TEST; METABOLITE; MONOAMINERGIC SYSTEM; NONHUMAN; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTI-INFECTIVE AGENTS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; FLUOXETINE; GLYCYRRHIZIC ACID; MALE; MAZE LEARNING; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS;

EID: 33645468480     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-006-0021-0     Document Type: Article

References (21)

1. Russian Patent No. 2180583, BIPM No. 8, 148 (2002).
2. K. S. Raevskii, T. D. Sotnikova, and R. R. Gainetdinov, "The brain dopaminergic system: Receptor heterogeneity, functional role, and pharmacological regulation," Usp. Fiziol. Nauk., 27, No. 4, 3-29 (1996).
3. P. Blier and C. De Montigny, "Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders," Neuropsychopharmacology, 21, Suppl. 1, S91-S98 (1999).
4. S. Caccia, C. Fracasso, S. Garattini, G. Guiso, and S. Sarati, "Effects of short-and long-term administration of fluoxetine on the monoamine content of rat brain," Neuropharmacology, 31, No. 4, 343-347 (1992).
5. J. A. Den Boer, "Social anxiety disorder/social phobia: epidemiology, diagnosis, neurobiology, and treatment," Comp. Psychiatry, 41, No. 6, 405-415 (2000).
6. B. Giros, M. Jaber, S. R. Jones, R. M. Wightman, and M. G. Caron, "Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter," Nature, 379, No. 6566, 606-612 (1996).
7. A. Gobert, J. M. Rivet, L. Cistarelli, C. Melon, and M. J. Millan, "Alpha2-adrenergic receptor blockade markedly potentiates duloxetine-and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats," J. Neurochem., 69, No. 6, 2616-2619 (1997).
8. A. Holmes, R. J. Yang, K. P. Lesch, J. N. Crawley, and D. L. Murray, "Mice lacking the serotonin transporter exhibit 5-HT(lA) receptor-mediated abnormalities in tests for anxiety-like behavior," Neuropsychopharmacology, 28, No. 12, 2077-2088 (2003).
9. Z. A. Hughes and S. C. Stanford, "Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex," Eur. J. Pharmacol., 317, No. 1, 83-90 (1996).
10. J. Ichikawa and H. Y. Meltzer, "Effect of antidepressants on striatal and accumbens extracellular dopamine levels," Eur. J. Pharmacol., 281, No. 3, 255-261 (1995).
11. S. Koch, K. W. Perry, D. L. Nelson, R. G. Conway, P. G. Threlkeld, and F. P. Bymaster, "R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: An in vivo microdialysis and receptor binding study," Neuropsychopharmacology, 27, No. 6, 949-959 (2002).
12. M. Kurt, A. C. Arik, and S. Celik, "The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice," J. Basic Clin. Physiol. Pharmacol., 11, No. 2, 173-180 (2000).
13. J. Mukherjee and Z. Y. Yang, "Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): An in vitro and in vivo study," Eur. J. Pharmacol., 337, No. 1, 111-114 (1997).
14. J. Mukherjee and Z. Y. Yang, "Monoamine oxidase A inhibition by fluoxetine: An in vitro and in vivo study," Synapse, 31, No. 4, 285-289 (1999).
15. K. W. Perry and R. W. Fuller, "Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-S04 and microdialysis in conscious rats," J. Neural. Transm., 104, No. 8-9, 953-966 (1997).
16. S. Prisco and E. Esposito, "Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area," Brit. J. Pharmacol., 116, No. 2, 1923-1931 (1995).
17. M. T. Silva, C. R. Alves, and E. M. Santarem, "Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze," Braz. J. Med. Biol. Res., 32, No. 3, 333-339 (1999).
18. R. C. Silva and M. L. Brandao, "Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: An ethological analysis," Pharmacol. Biochem. Behav., 65, No. 2, 209-216 (2000).
19. C. Spielewoy, C. Roubert, M. Hamon, M. Nosten-Bertrand, C. Betancur, and B. Giros, "Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice," Behav. Pharmacol., 11, No. 3-4 279-290 (2000).
20. D. Spinks and G. Spinks, "Serotonin reuptake inhibition: An update on current research strategies," Curr. Med. Chem., 9, No. 8, 799-810 (2002).
21. A. Zocchi, G. Varnier, R. Arban, C. Griffante, L. Zanetti, L. Bettelini, M. Marchi, P. A. Gerrard, and M. Corsi, "Effects of antidepressant drugs and GR 205171, a neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse," Neurosci. Lett., 345, No. 2, 73-76 (2003).